These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 20077523)

  • 21. Health effects of nanomaterials.
    Tetley TD
    Biochem Soc Trans; 2007 Jun; 35(Pt 3):527-31. PubMed ID: 17511644
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Nanomaterials for environmental remediation: investigating the role of nanoinformatics in support of environmental, health, and safety oversight of nanotechnologies at the local level.
    Massawe E
    J Environ Health; 2013; 76(1):8-17. PubMed ID: 23947284
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Health and safety implications of occupational exposure to engineered nanomaterials.
    Stebounova LV; Morgan H; Grassian VH; Brenner S
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2012; 4(3):310-21. PubMed ID: 22131295
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Chemicals of emerging concern in the Great Lakes Basin: an analysis of environmental exposures.
    Klecka G; Persoon C; Currie R
    Rev Environ Contam Toxicol; 2010; 207():1-93. PubMed ID: 20652664
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A rationale and framework for establishing the quality of human exposure assessments.
    Hawkins NC; Jayjock MA; Lynch J
    Am Ind Hyg Assoc J; 1992 Jan; 53(1):34-41. PubMed ID: 1590219
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The contrast between risk assessment and rules of evidence in the context of international trade disputes: can the US experience inform the process?
    Anderson EL; Hilaire CS
    Risk Anal; 2004 Apr; 24(2):449-59. PubMed ID: 15078316
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Health impact and safety of engineered nanomaterials.
    Teow Y; Asharani PV; Hande MP; Valiyaveettil S
    Chem Commun (Camb); 2011 Jul; 47(25):7025-38. PubMed ID: 21479319
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Occupational risk management of engineered nanoparticles.
    Schulte P; Geraci C; Zumwalde R; Hoover M; Kuempel E
    J Occup Environ Hyg; 2008 Apr; 5(4):239-49. PubMed ID: 18260001
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Workplace practices for engineered nanomaterial manufacturers.
    Woskie S
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2010; 2(6):685-92. PubMed ID: 20593453
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Guidance for handling and use of nanomaterials at the workplace.
    Heinemann M; Schäfer HG
    Hum Exp Toxicol; 2009 Jun; 28(6-7):407-11. PubMed ID: 19755453
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Biomonitoring for occupational health risk assessment (BOHRA).
    Manno M; Viau C; ; Cocker J; Colosio C; Lowry L; Mutti A; Nordberg M; Wang S
    Toxicol Lett; 2010 Jan; 192(1):3-16. PubMed ID: 19446015
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A global view of regulations affecting nanomaterials.
    Hansen SF
    Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2010; 2(5):441-9. PubMed ID: 20533518
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Analysis of the occupational, consumer and environmental exposure to engineered nanomaterials used in 10 technology sectors.
    Nowack B; Brouwer C; Geertsma RE; Heugens EH; Ross BL; Toufektsian MC; Wijnhoven SW; Aitken RJ
    Nanotoxicology; 2013 Sep; 7(6):1152-6. PubMed ID: 22783888
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Occupational safety and health's role in sustainable, responsible nanotechnology: gaps and needs.
    Iavicoli S; Rondinone BM; Boccuni F
    Hum Exp Toxicol; 2009 Jun; 28(6-7):433-43. PubMed ID: 19755456
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Modeling approaches for characterizing and evaluating environmental exposure to engineered nanomaterials in support of risk-based decision making.
    Hendren CO; Lowry M; Grieger KD; Money ES; Johnston JM; Wiesner MR; Beaulieu SM
    Environ Sci Technol; 2013 Feb; 47(3):1190-205. PubMed ID: 23293982
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Organizing the supervision over the turnover of nanomaterials presenting a potential hazard to human health].
    Onishchenko GG
    Gig Sanit; 2011; (2):4-9. PubMed ID: 21604392
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Toward the development of decision supporting tools that can be used for safe production and use of nanomaterials.
    Som C; Nowack B; Krug HF; Wick P
    Acc Chem Res; 2013 Mar; 46(3):863-72. PubMed ID: 23110540
    [TBL] [Abstract][Full Text] [Related]  

  • 38. How to anticipate the assessment of the public health benefit of new medicines?
    Massol J; Puech A; Boissel JP;
    Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Development of a preliminary framework for informing the risk analysis and risk management of nanoparticles.
    Morgan K
    Risk Anal; 2005 Dec; 25(6):1621-35. PubMed ID: 16506988
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk assessment of engineered nanomaterials and nanotechnologies--a review.
    Savolainen K; Alenius H; Norppa H; Pylkkänen L; Tuomi T; Kasper G
    Toxicology; 2010 Mar; 269(2-3):92-104. PubMed ID: 20105448
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.